This article has Open Peer Review reports available.
A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer
© Hosein et al.; licensee BioMed Central. 2015
Received: 27 May 2014
Accepted: 23 February 2015
Published: 15 March 2015
Cancer-associated fibroblasts (CAFs) play an important role in breast cancer pathogenesis by paracrine regulation of breast cancer cell biology. Several in vitro and mouse models have characterized the role of cell contact and cytokine molecules mediating this relationship, although few reports have used human CAFs from breast tumors.
Primary breast CAF cultures were established and gene expression profiles analysed in order to guide subsequent co-culture models. We used a combination of colorimetric proliferation assays and gene expression profiling to determine the effect of CAFs on the MCF-7 breast cancer cell in an indirect co-culture system.
Using gene expression profiling, we found that a subgroup of breast CAFs are positive for a type one interferon response, confirming previous reports of an activated type one interferon response in whole tumor datasets. Interferon positive breast cancer patients show a poor prognostic outcome in an independent microarray dataset. In addition, CAFs positive for the type one interferon response promoted the growth of the MCF-7 breast cancer cell line in an indirect co-culture model. The addition of a neutralizing antibody against the ligand mediating the type one response in fibroblasts, interferon-β, reverted this co-culture phenotype. CAFs not expressing the interferon response genes also promoted the growth of the MCF-7 breast cancer cell line but this phenotype was independent of the type one fibroblast interferon ligand.
Primary breast CAFs show inter-patient molecular heterogeneity as evidenced by interferon response gene elements activated in a subgroup of CAFs, which result in paracrine pro-proliferative effects in a breast cancer cell line co-culture model.
Breast carcinoma is orchestrated by a complex series of molecular events and biological processes involving the contributions of several cell types [1,2]. Despite the fact that most of our understanding of cancer centers on those events taking place within the cancer epithelium, the cancer-associated stroma also plays a co-dominant role in shaping the biological and clinical fates of the disease [3,4]. Specifically, the carcinoma-associated fibroblast (CAF) has been shown to be a major player in the stroma’s influence on tumor growth [5,6]. Many reports have focused on the role that CAFs have in regulating TGF-β signalling and angiogenesis through secreted factors such as SDF-1 and VEGF [7-9]. CAFs have shown the ability to both promote  and repress  MCF-7 cell growth in vitro, in addition to having no effect at all . Importantly, none of these studies took account of possible inter-patient CAF heterogeneity largely because, unlike tumor heterogeneity, little data exists about inter-patient CAF heterogeneity.
In particular, one in vitro model using a series of breast cancer cell lines directly co-cultured with normal human fibroblasts demonstrated that human fibroblasts will induce a type-one interferon response when admixed with tumorigenic breast cancer cell lines . Furthermore, this type-one interferon response signature was shown to be expressed in a large proportion of breast tumors contained in the NKI breast tumor microarray dataset  and its expression in whole breast tumors was associated with a significantly poorer prognosis. In addition, this outcome was confirmed in an independent patient cohort in which immunohistochemical analysis of phospho-STAT1 was used as a proxy for the presence of the type-one interferon response.
In this report we show that there exists a subset of CAFs which express a type one interferon response which is stable upon ex vivo cultivation. This interferon response can impart a paracrine growth-promoting effect on the MCF-7 breast cancer cell line. Our findings suggest that an understanding of CAF molecular heterogeneity can be used to construct relevant preclinical in vitro models of tumor-stromal interactions.
Primary tissue culture was carried out as previously outlined . Briefly, invasive breast carcinoma specimens were surgically resected from patients at the Jewish General Hospital (Montreal, Canada). CAFs were determined to be intratumoral by a certified pathologist. Tissues were minced with a sterile blade and resuspended in a solution of DMEM with 10% fetal bovine serum (FBS) and 3% collagenase overnight at 37 degrees Celsius. The next day samples were filtered through an 8 μm mesh in order to remove undigested debris. The single cell suspension with viable fibroblasts was cultured in DMEM (10% FBS) for 2–3 weeks in a 24 well plate and then transferred to a T75 flask where it was continually maintained in a 2% FBS medium solution. All fibroblasts were harvested between passage doublings 3–5. Normal breast fibroblasts from reduction mammoplasties were collected at the same institution and in the same manner as the CAFs noted above. All fibroblast cultures underwent immunocytochemical analyses for pan-cytokeratin and vimentin as previously described by our group to confirm their mesenchymal identity . All protocols involving human tissues were approved by the Research Ethics Committee of the Lady Davis Institute for Medical Research of McGill University and were in compliance with the Helsinki Declaration. Furthermore, all tissues procured from both reduction mammoplasty and tumor resection surgeries were obtained with the written informed consent of all patients.
DNA microarray expression profiling
Gene expression profiling was carried out as described previously . Briefly, fibroblasts were harvested from subconfluent cultures, cultivated in DMEM with 2% FBS. RNA was then extracted using the Mini RNA Extraction kit (Qiagen, Venlo, Netherlands). Five micrograms of total RNA was reversed transcribed with the Fairplay III Microarray Labeling kit according to the instructions of the manufacturer (Aglient Technologies, Santa Clara, California). The resulting cDNA was then precipitated with 70% ethanol, air-dried, resuspended in 5 μL of coupling buffer, and dissolved at 37°C for 15 minutes. Five microliters of Cy3 or Cy5 dye were added to the universal reference (Aglient Technologies) or fibroblast cDNA, respectively, and allowed to incorporate for 30 minutes at room temperature. Labeled cDNA was cleaned-up using Fairplay columns (Aglient Technologies) according to the instructions of the manufacturer. Labeled reference and fibroblast cDNA samples were combined and mixed with gene expression hybridization buffer and control targets supplied by the manufacturer and hybridized to a 4 × 44 K two-color whole human genome gene expression array for 17 hours at 65°C. The array was then washed in a solution of 6× SSPE, 0.005% N-lauroylsarcosine followed by a solution of 0.06× SSPE, 0.005% lauroylsarcosine and scanned on the Agilent DNA Microarray scanner at a resolution of 5 μm. All images were extracted and normalized with Feature Extraction software version 9.5. The microarray data from this study have been submitted to the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE29270.
Analysis of fibroblast and Co-culture expression profiling data
Breast carcinoma derived fibroblasts were cultured and expression profiled as outlined previously by our group . This dataset was analyzed using the straight-forward approach demonstrated by Sorlie and colleagues : any gene that was two-fold above the median value for that gene in at least 3 patient samples was retained. Unsupervised clustering (Pearson’s correlation) was then performed using TIGR MeV version 4.1. In the case of the expression profiling on the MCF-7 breast cancer cell line, the three conditions (see below) were compared in a supervised 2 × 2 × 2 manner using the SAM algorithm . The samples were then clustered in the same way as the unsupervised manner. This was also carried out by using TIGR MeV version 4.1.
Interferon-β Enzyme Linked Immunosorbant Assay (ELISA)
Subconfluent fibroblast cultures were allowed to incubate in DMEM (2% FBS) for 48 hours at which time the medium was collected and spun down for five minutes at 1500 rpm in order to remove debris. An ELISA assay was carried out as per the manufacturer’s instructions using the Human Interferon-β kit (R&D Systems, Minneapolis, Minnesota).
In vitro co-culture model
All experiments were carried out in DMEM media supplemented with 2% fetal bovine serum. 5000 MCF-7 cells (American Tissue Type Collection, Manassas, Virginia) were plated into flat bottom 24-well plates and allowed to adhere overnight. 600 μl of fresh media was then added and a semi-permeable insert with a 0.4 μm pore size (Millipore, Billerica, Massachusetts) was placed over the media. 5000 fibroblasts were then seeded into the insert, re-suspended in 400 μl of media for a total co-culture volume of 1 ml/well. Monoclonal antibodies (R&D Systems, Minneapolis, MN) were added at this time if necessary. After co-cultures had incubated for the appropriate time, inserts and fibroblasts were removed and MTT reagent (Sigma-Aldrich, St. Louis, Missouri) was added to the media (1:10 ratio) and allowed to incubate for 2 hours after which the media was aspirated and 1 ml of DMSO was added. The absorbance was measured at 570 nm. For RNA or protein harvesting, co-cultures were performed in 6-well dishes with appropriate transwell insert (Millipore) using 25,000 of each cell type in a total co-culture volume of 4 ml. After the appropriate co-incubation time, cells were snap frozen in liquid nitrogen for RNA harvesting.
Quantitative Reverse Transcription Polymerase Chain Reaction (Q-RT-PCR)
Five micrograms of total RNA was reverse transcribed using Stratagene’s AffinityScript Multiple Temperature cDNA Synthesis Kit (Agilent Technologies) according to the manufacturer’s instructions. 1 μl of oligo(dT) primer was added to 5ug of total RNA and allowed to incubate at 65°C for five minutes. The reaction was subsequently cooled to room temperature. The following reactants were then added for a total volume of 20 μl : 2.0 μl of 10× AffinityScript RT Buffer, 0.8 μl of dNTP mix (25 mM of each dNTP), 0.5 μl of RNase Block Ribonuclease Inhibitor (40 U/μl) and 1 μl of reverse transcriptase. The reaction was carried out at 42°C for one hour and terminated by a 15 minute incubation at 70°C. The parameters for the interferon-associated Q-RT-PCR were adapted from Buess et al. . PCR reactions were carried out in a final volume of 10 μl. Two micrograms of synthesized cDNA, 5 μl of 2× SYBR ®Green PCR Master Mix (ABI, Foster City, CA, USA) and 1 μl (10 μM ) of each primer (sequences: OAS2, forward GGAATACCTGAAGCCCTACGAA, reverse CCTGCAGACGTCACAGATGGT; IFNβ, forward ACCTCCGAAACTGAAGATCTCCTA, reverse TGCTGGTTGAAGAATGCTTGA; GAPDH, forward GAAGGTGAAGGTCGGAGTC, reverse GAAGATGGTGATGGGATTTC). Primers were purchased from Invitrogen (Carlsbad, California) and adapted from Buess et al. All reactions were carried out in an ABI 7700 Sequence Detection System using the following amplification conditions: 50°C for 2 minutes, 94°C for 10 minutes, followed by 40 cycles of 94°C for 15 s and 60°C for 60 seconds. All reactions were carried out in triplicate.
NKI295 database analysis
Patients were split into high and low expressers of our IFN signature by hierarchical clustering. Hierarchical clustering was performed using Euclidean and Ward’s algorithm. A univariate Kaplan Meier analysis was then carried out in order to assess the prognostic significance of the IFN signature. Secondly, patients in the NKI patient cohort were split into two groups (high and low) based on their expression of S100A2 using hierarchical clustering. The low and high S100A2 expresser groups were separately clustered with the IFN signature. Kaplan Meier curves were subsequently generated.
Gene expression profiling reveals the presence of a CAF subtype that is positive for a type one interferon response
Carcinoma-associated fibroblasts impart pro-cancer effects on the MCF-7 breast cancer cell line in an indirect heterotypic co-culture system
The pro-MCF-7 effects by IFN-positive CAFs are dependent on the continued action of the IFN-β ligand whereas this is not a requirement for the pro-MCF-7 effects of the IFN-negative CAFs
Microarray analysis of the IFN-positive-CAF-MCF-7 co-cultures reveals the presence of the candidate tumor suppressor gene S100A2 as a putative mediator of the pro-cancer heterotypic phenotype
The tumor microenvironment has been recognized as a major player in the development and progression of solid tumors, including breast cancer. Recently, targeting immune cells within the tumor microenvironment has led to spectacular successes in the treatment of melanomas [22,23]. The role of interferons in modulating the immune response to viruses is well known, but the role of interferons in modulating the immune response to tumors is less well defined. Early experimental models have uncovered potent direct cytotoxic and/or anti-proliferative effects of interferons [24-27], although the translation of these findings into their use as anti-cancer therapeutics [28-30] has been met with only limited success in breast cancer  and other carcinomas . In fact, there were even early indications that the administration of IFN-β to cancer patients could lead to an increase in the number of hormone receptors in the cancerous tissue . More recently, the presence of aberrantly expressed IFN-related genes in cancer were first noticed in the initial molecular portraits of breast cancer . Later an IFN signature was observed in several human cancers; 15% of childhood lymphoblastic leukemias, 20% of ovarian and 40% of breast cancers were positive for an IFN-related signature .
In the current study we have shown that a subset of breast CAFs (5 of 23 tested CAFs) strongly expresses a type one interferon response and that this response, chiefly through the IFN-β cytokine, can impart a pro-proliferative effect on MCF-7 breast cancer cells in vitro. It should be noted that direct fibroblast-breast cancer cell line contact was necessary when the interferon response was previously induced artificially in vitro . We show that an interferon response is identifiable even after ex-vivo culturing in some CAFs grown alone, and that its pro-proliferative effect on co-cultured breast cancer cells is mediated through the action of soluble IFN-β ligand. Our IFN response can be detected in whole breast tumors as an expression signature conveying poor prognosis. Additionally, we showed that S100A2 is a candidate mediator of the IFN response’s effect on patient outcome. S100A2 is a calcium binding protein that has been repeatedly shown to be down regulated in a variety of cancers such as breast , and prostate  and is considered to be a candidate tumor suppressor gene.
In light of recent findings that interferon positivity correlates with a poor clinical outcome in breast cancer , it is probable that interferons may actually be pro-tumorigenic, as suggested also by our findings. Type one interferon signaling has also been correlated with resistance to doxorubicin and topoisomerase-II inhibitors in vitro  and confer resistance to DNA damage in cancer cell lines . Taken together, this would suggest that type one interferon neutralization within the tumor microenvironment should be pursued in lieu of their supplementation at least in cases in which interferon signalling is active and detectable in the tumor microenvironment . Moreover, on close inspection of the interferon response gene set we have identified there are many cytokines present (CXCL1, CXCL2, CXCL6, CXCL10, CXCL11, IL6, IL8, CSF2, CCL11), any one of which could be mediating the phenotype seen herein.
We have identified a subset of CAFs and perhaps breast tumors, which may be particularly vulnerable to such therapeutic approaches. These data will need to be further expanded to include in vivo models of human CAFs co-implanted with breast cancer cell lines. Taken together, these results provide a better understanding of the potential value of targeted anti-IFN-β therapy in breast cancer patients whose tumors show a gene expression profile reflecting a type-one IFN response. Protein biomarkers such as S100A2, OAS2 and/or IFNβ RNA expression in breast tumors may prove to be useful guides in predicting the response of IFN-positive patients to anti-interferon therapeutics.
We would like to thank the FRQS Reseau de Recherche sur le Cancer and the Jewish General Hospital Foundation-Weekend to End Breast Cancer Fund for their generous funding of this work.
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.View ArticlePubMedGoogle Scholar
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.View ArticlePubMedGoogle Scholar
- Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518–27.View ArticlePubMedGoogle Scholar
- Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15(1):68–74.View ArticlePubMedGoogle Scholar
- Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392–401.View ArticlePubMedGoogle Scholar
- Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, et al. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS One. 2013;8(4):e61353.View ArticlePubMedPubMed CentralGoogle Scholar
- Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303(5659):848–51.View ArticlePubMedGoogle Scholar
- Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.View ArticlePubMedGoogle Scholar
- Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010;107(46):20009–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Adams EF, Newton CJ, Braunsberg H, Shaikh N, Ghilchik M, James VH. Effects of human breast fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of MCF-7 cells in culture. Breast Cancer Res Treat. 1988;11(2):165–72.View ArticlePubMedGoogle Scholar
- van Roozendaal KE, Klijn JG, van Ooijen B, Claassen C, Eggermont AM, Henzen-Logmans SC, et al. Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer. 1996;65(1):120–5.View ArticlePubMedGoogle Scholar
- Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM, et al. Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer. 1997;71(1):42–8.View ArticlePubMedGoogle Scholar
- Buess M, Nuyten DS, Hastie T, Nielsen T, Pesich R, Brown PO. Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol. 2007;8(9):R191.View ArticlePubMedPubMed CentralGoogle Scholar
- van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.View ArticlePubMedGoogle Scholar
- Hosein AN, Wu M, Arcand SL, Lavallee S, Hebert J, Tonin PN, et al. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res. 2010;70(14):5770–7.View ArticlePubMedGoogle Scholar
- Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98(9):5116–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.View ArticlePubMedGoogle Scholar
- Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004;2(2):E7.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proc Natl Acad Sci U S A. 1992;89(6):2504–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Expression of calcium-binding protein S100A2 in breast lesions. Br J Cancer. 2000;83(11):1473–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. 1998;273(52):35056–62.View ArticlePubMedGoogle Scholar
- Demers GW, Johnson DE, Machemer T, Looper LD, Batinica A, Beltran JC, et al. Tumor growth inhibition by interferon-alpha using PEGylated protein or adenovirus gene transfer with constitutive or regulated expression. Mol Ther. 2002;6(1):50–6.View ArticlePubMedGoogle Scholar
- Endou M, Mizuno M, Nagata T, Tsukada K, Nakahara N, Tsuno T, et al. Growth inhibition of human pancreatic cancer cells by human interferon-beta gene combined with gemcitabine. Int J Mol Med. 2005;15(2):277–83.PubMedGoogle Scholar
- Ozzello L, Habif DV, DeRosa CM. Antiproliferative effects of natural interferon beta alone and in combination with natural interferon gamma on human breast carcinomas in nude mice. Breast Cancer Res Treat. 1990;16(2):89–96.View ArticlePubMedGoogle Scholar
- Sikora K. Does interferon cure cancer? Br Med J. 1980;281(6244):855–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Borden EC, Balkwill FR. Preclinical and clinical studies of interferons and interferon inducers in breast cancer. Cancer. 1984;53(3 Suppl):783–9.View ArticlePubMedGoogle Scholar
- Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1991;18(3):165–70.View ArticlePubMedGoogle Scholar
- Bulbul MA, Huben RP, Murphy GP. Interferon-beta treatment of metastatic prostate cancer. J Surg Oncol. 1986;33(4):231–3.View ArticlePubMedGoogle Scholar
- Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Fridman WH, Magdelenat H, et al. Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors. Eur J Cancer Clin Oncol. 1982;18(10):929–35.View ArticlePubMedGoogle Scholar
- Einav U, Tabach Y, Getz G, Yitzhaky A, Ozbek U, Amariglio N, et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene. 2005;24(42):6367–75.PubMedGoogle Scholar
- Ilg EC, Schafer BW, Heizmann CW. Expression pattern of S100 calcium-binding proteins in human tumors. Int J Cancer. 1996;68(3):325–32.View ArticlePubMedGoogle Scholar
- Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol. 2003;21(1):106–12.View ArticlePubMedGoogle Scholar
- Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, et al. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer. 2005;93(4):483–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, et al. IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 2013;32(20):2751–63.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.